Skip to content
OpenCapital
Get started

Nuvation Bio NUVB AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
——
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Nuvation Bio's AFS and trading securities - unrealized loss position (>=12 months) fair value?
Nuvation Bio (NUVB) reported AFS and trading securities - unrealized loss position (>=12 months) fair value of $0 in Q4 2025.
How has Nuvation Bio's AFS and trading securities - unrealized loss position (>=12 months) fair value changed year-over-year?
Nuvation Bio's AFS and trading securities - unrealized loss position (>=12 months) fair value decreased by 100.0% year-over-year, from $55.01M to $0.